{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:20:54Z","timestamp":1788402054588,"version":"build-2803163510"},"reference-count":108,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merilyn Hester Scholarship"},{"name":"Leon Kenneth Knoebel Fellowship"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA27370"],"award-info":[{"award-number":["T32CA27370"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001279","name":"Orthopaedic Research and Education Foundation","doi-asserted-by":"publisher","award":["OREF-RCSTG"],"award-info":[{"award-number":["OREF-RCSTG"]}],"id":[{"id":"10.13039\/100001279","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dudley P Allen Fellowship"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004402"],"award-info":[{"award-number":["UM1TR004402"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011749","name":"Melvin and Bren Simon Cancer Center, Indiana University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011749","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Big Ten Cancer Research Consortium Foundation Kenneth and Verna Mae Jessen Award"},{"name":"Strides for Sarcoma"},{"DOI":"10.13039\/100003287","name":"Rally Foundation for Childhood Cancer Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Angie Fowler AYA Cancer Research Fund"},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA2100123"],"award-info":[{"award-number":["CA2100123"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA230160"],"award-info":[{"award-number":["CA230160"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Danaher Foundation"},{"name":"Caroline Symmes Children\u2019s Cancer Endowment"},{"name":"Tyler Trent Cancer Research Endowment"},{"DOI":"10.13039\/100011749","name":"Melvin and Bren Simon Cancer Center, Indiana University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011749","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA209304"],"award-info":[{"award-number":["R21CA209304"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA082709"],"award-info":[{"award-number":["CA082709"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Osteosarcoma is the most common primary malignant bone tumor and predominantly affects adolescents and young adults. It is the third most common cause of cancer-related deaths among 9 to 24 year olds. Despite aggressive chemotherapeutic and surgical therapies, the survival rate is only 25% for patients with detectable lung metastases at diagnosis and only 70% in patients who present without detectable lung metastases. The poor prognosis is due to growth of metastases irrespective of whether they are initially large enough to detect clinically. It is therefore necessary to develop new methods to target the growth of lung micrometastases. An NCI panel of FDA-approved oncology drugs was therefore screened using three highly metastatic human osteosarcoma cell lines. To more closely approximate in vivo micrometastases, the screen used a three-dimensional multicellular in vitro osteosarcoma spheroid (sarcosphere) model. Among 13 hits from the initial screen, we identified the histone deacetylase inhibitor (HDI) romidepsin as the most promising inhibitor in secondary screens comparing effects on sarcospheres with clinically achievable levels and to effects on non-transformed cells. Romidepsin potency was evident with and without standard-of-care chemotherapeutics (MAP: methotrexate, adriamycin, and cisplatin) at romidepsin concentrations that are clinically achievable and did not affect non-transformed cells. Romidepsin also substantially outperformed the other three FDA-approved HDIs and eight HDIs in clinical trials. The effects of romidepsin were a transient cell cycle block at G2\/M and cell death. Importantly, sarcospheres derived from \u223c30% of human and 50% of canine patient samples responded to romidepsin at clinically tolerable concentrations (ED50s &amp;lt;70 nmol\/L).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Our unbiased sarcosphere-based drug screen identified romidepsin as a promising candidate to repurpose for human and canine patients with metastatic osteosarcoma. This screening strategy allowed us to identify romidepsin-sensitive and -resistant patients. Sarcosphere-based screening may therefore be useful to identify patients most likely to respond clinically to romidepsin or other drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0121","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T16:57:54Z","timestamp":1757955474000},"page":"1821-1838","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4578-899X","authenticated-orcid":false,"given":"Emily E.","family":"Seiden","sequence":"first","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"2Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"4Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5554-4799","authenticated-orcid":false,"given":"Spencer M.","family":"Richardson","sequence":"additional","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"2Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0198-2512","authenticated-orcid":false,"given":"Leah A.","family":"Everitt","sequence":"additional","affiliation":[{"name":"5Department of Orthopaedics, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4108-4663","authenticated-orcid":false,"given":"Gabrielle J.","family":"Knafler","sequence":"additional","affiliation":[{"name":"5Department of Orthopaedics, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7896-4881","authenticated-orcid":false,"given":"Alyssa L.","family":"Walker","sequence":"additional","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7071-119X","authenticated-orcid":false,"given":"Venetia A.","family":"Whiteside","sequence":"additional","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3738-5609","authenticated-orcid":false,"given":"Divya","family":"Pillutla","sequence":"additional","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6802-2405","authenticated-orcid":false,"given":"Shrey","family":"Ramnath","sequence":"additional","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5747-8384","authenticated-orcid":false,"given":"Gavin P.","family":"Kinsella","sequence":"additional","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6152-1043","authenticated-orcid":false,"given":"Piper A.","family":"Wilburn","sequence":"additional","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"4Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8256-0779","authenticated-orcid":false,"given":"James D.","family":"Buschbach","sequence":"additional","affiliation":[{"name":"5Department of Orthopaedics, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6312-6091","authenticated-orcid":false,"given":"Deep A.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"5Department of Orthopaedics, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-7970","authenticated-orcid":false,"given":"M. Reza","family":"Saadatzadeh","sequence":"additional","affiliation":[{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"6Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6341-492X","authenticated-orcid":false,"given":"L. Daniel","family":"Wurtz","sequence":"additional","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"4Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2716-3032","authenticated-orcid":false,"given":"Patrick J.","family":"Getty","sequence":"additional","affiliation":[{"name":"5Department of Orthopaedics, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6557-418X","authenticated-orcid":false,"given":"Sheldon L.","family":"Padgett","sequence":"additional","affiliation":[{"name":"8Metropolitan Veterinary Hospital, Akron, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6017-5206","authenticated-orcid":false,"given":"Rance M.","family":"Gamblin","sequence":"additional","affiliation":[{"name":"8Metropolitan Veterinary Hospital, Akron, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-4679","authenticated-orcid":false,"given":"Michael O.","family":"Childress","sequence":"additional","affiliation":[{"name":"9Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana."},{"name":"10College of Veterinary Medicine, Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana."},{"name":"11Evan and Sue Ann Werling Comparative Oncology Research Center, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4201-821X","authenticated-orcid":false,"given":"Christopher M.","family":"Fulkerson","sequence":"additional","affiliation":[{"name":"9Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana."},{"name":"10College of Veterinary Medicine, Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana."},{"name":"11Evan and Sue Ann Werling Comparative Oncology Research Center, Purdue University, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-5221","authenticated-orcid":false,"given":"Maegan L.","family":"Capitano","sequence":"additional","affiliation":[{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"12Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-5707","authenticated-orcid":false,"given":"Karen E.","family":"Pollok","sequence":"additional","affiliation":[{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"6Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"13Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"14Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2639-4290","authenticated-orcid":false,"given":"Christopher D.","family":"Collier","sequence":"additional","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"4Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"5Department of Orthopaedics, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-983X","authenticated-orcid":false,"given":"Edward M.","family":"Greenfield","sequence":"additional","affiliation":[{"name":"1Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"2Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"3Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"4Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, Indiana."},{"name":"5Department of Orthopaedics, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2025101505574819800_bib1","article-title":"SEER research data 1973\u20132012","author":"Surveillance, Epidemiology, and End Results (SEER) Program"},{"key":"2025101505574819800_bib2","doi-asserted-by":"crossref","first-page":"704872","DOI":"10.1155\/2012\/704872","article-title":"A meta-analysis of osteosarcoma outcomes in the modern medical era","volume":"2012","author":"Allison","year":"2012","journal-title":"Sarcoma"},{"key":"2025101505574819800_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.5435\/00124635-200908000-00005","article-title":"Osteosarcoma","volume":"17","author":"Messerschmitt","year":"2009","journal-title":"J Am Acad Orthop Surg"},{"key":"2025101505574819800_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-04843-7_1","article-title":"Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma","volume":"804","author":"Jaffe","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"2025101505574819800_bib5","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.3390\/cancers12092426","article-title":"Systems biology approach identifies prognostic signatures of poor overall survival and guides the prioritization of novel BET-CHK1 combination therapy for osteosarcoma","volume":"12","author":"Pandya","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025101505574819800_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","article-title":"Genome-informed targeted therapy for osteosarcoma","volume":"9","author":"Sayles","year":"2019","journal-title":"Cancer Discov"},{"key":"2025101505574819800_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1615\/CritRevOncog.2015013713","article-title":"Osteosarcoma genetics and epigenetics: emerging biology and candidate therapies","volume":"20","author":"Morrow","year":"2015","journal-title":"Crit Rev Oncog"},{"key":"2025101505574819800_bib8","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.1038\/ncomms9940","article-title":"Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency","volume":"6","author":"Kovac","year":"2015","journal-title":"Nat Commun"},{"key":"2025101505574819800_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40272-015-0134-4","article-title":"Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy","volume":"17","author":"Rivera-Valentin","year":"2015","journal-title":"Paediatr Drugs"},{"key":"2025101505574819800_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","article-title":"Cancer drug discovery by repurposing: teaching new tricks to old dogs","volume":"34","author":"Gupta","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"2025101505574819800_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tibtech.2012.12.003","article-title":"Spheroid culture as a tool for creating 3D complex tissues","volume":"31","author":"Fennema","year":"2013","journal-title":"Trends Biotechnol"},{"key":"2025101505574819800_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/mc.21844","article-title":"In vitro three-dimensional (3D) models in cancer research: an update","volume":"52","author":"Kimlin","year":"2013","journal-title":"Mol Carcinog"},{"key":"2025101505574819800_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jbiotec.2014.09.005","article-title":"An in vitro osteosarcoma 3D microtissue model for drug development","volume":"189","author":"Rimann","year":"2014","journal-title":"J Biotechnol"},{"key":"2025101505574819800_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","article-title":"Multicellular tumor spheroids: an underestimated tool is catching up again","volume":"148","author":"Hirschhaeuser","year":"2010","journal-title":"J Biotechnol"},{"key":"2025101505574819800_bib15","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/pmic.201300053","article-title":"Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system","volume":"13","author":"Arai","year":"2013","journal-title":"Proteomics"},{"key":"2025101505574819800_bib16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/ijms19020615","article-title":"Sarcoma spheroids and organoids-promising tools in the era of personalized medicine","volume":"19","author":"Colella","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025101505574819800_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nprot.2008.226","article-title":"Spheroid-based drug screen: considerations and practical approach","volume":"4","author":"Friedrich","year":"2009","journal-title":"Nat Protoc"},{"key":"2025101505574819800_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fonc.2017.00203","article-title":"Three-Dimensional patient-derived in vitro sarcoma models: promising tools for improving clinical tumor management","volume":"7","author":"Gaebler","year":"2017","journal-title":"Front Oncol"},{"key":"2025101505574819800_bib19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1177\/1087057106292763","article-title":"Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis","volume":"11","author":"Ivascu","year":"2006","journal-title":"J Biomol Screen"},{"key":"2025101505574819800_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-017-0663-5","article-title":"Relevance of 3d culture systems to study osteosarcoma environment","volume":"37","author":"De Luca","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"2025101505574819800_bib21","first-page":"266","article-title":"Modeling physiological events in 2D vs. 3D cell culture","volume":"32","author":"Duval","year":"2017","journal-title":"Physiology (Bethesda)"},{"key":"2025101505574819800_bib22","doi-asserted-by":"crossref","first-page":"1021966","DOI":"10.3389\/fbioe.2022.1021966","article-title":"Advances in the application of 3D tumor models in precision oncology and drug screening","volume":"10","author":"Guan","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"2025101505574819800_bib23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1007\/s11999.0000000000000059","article-title":"Micrometastatic drug screening platform shows heterogeneous response to MAP chemotherapy in osteosarcoma cell lines","volume":"476","author":"Collier","year":"2018","journal-title":"Clin Orthop Relat Res"},{"key":"2025101505574819800_bib24","doi-asserted-by":"crossref","first-page":"29469","DOI":"10.18632\/oncotarget.5177","article-title":"Characterization of the metastatic phenotype of a panel of established osteosarcoma cells","volume":"6","author":"Ren","year":"2015","journal-title":"Oncotarget"},{"key":"2025101505574819800_bib25","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-13-2574","article-title":"Toward a drug development path that targets metastatic progression in osteosarcoma","volume":"20","author":"Khanna","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2025101505574819800_bib26","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/cncr.25884","article-title":"Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases","volume":"117","author":"Koshkina","year":"2011","journal-title":"Cancer"},{"key":"2025101505574819800_bib27","first-page":"301","article-title":"Recent and current clinical trials in canine appendicular osteosarcoma","volume":"61","author":"Poon","year":"2020","journal-title":"Can Vet J"},{"key":"2025101505574819800_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13028-017-0341-9","article-title":"Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics","volume":"59","author":"Simpson","year":"2017","journal-title":"Acta Vet Scand"},{"key":"2025101505574819800_bib29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/978-1-4419-0284-9_24","article-title":"Bridging the gap between experimental animals and humans in osteosarcoma","volume":"152","author":"Withrow","year":"2009","journal-title":"Cancer Treat Res"},{"key":"2025101505574819800_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/1471-2164-10-625","article-title":"Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression","volume":"10","author":"Paoloni","year":"2009","journal-title":"BMC Genomics"},{"key":"2025101505574819800_bib31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/jvim.12313","article-title":"Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma","volume":"28","author":"Selmic","year":"2014","journal-title":"J Vet Intern Med"},{"key":"2025101505574819800_bib32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10585-005-0365-9","article-title":"An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis","volume":"22","author":"Luu","year":"2005","journal-title":"Clin Exp Metastasis"},{"key":"2025101505574819800_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/A:1006767007547","article-title":"An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential","volume":"18","author":"Khanna","year":"2000","journal-title":"Clin Exp Metastasis"},{"key":"2025101505574819800_bib34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10585-005-0599-6","article-title":"Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells","volume":"21","author":"Duan","year":"2004","journal-title":"Clin Exp Metastasis"},{"key":"2025101505574819800_bib35","first-page":"53884","article-title":"Establishment of cancer stem cell cultures from human conventional osteosarcoma","volume":"116","author":"Palmini","year":"2016","journal-title":"J Vis Exp"},{"key":"2025101505574819800_bib36","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/0008-5472.CAN-14-0247","article-title":"Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes","volume":"74","author":"Hall","year":"2014","journal-title":"Cancer Res"},{"key":"2025101505574819800_bib37","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2025101505574819800_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"key":"2025101505574819800_bib39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2025101505574819800_bib40","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025101505574819800_bib41","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-13-0735","article-title":"First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors","volume":"19","author":"Brunetto","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025101505574819800_bib42","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1080\/10428194.2017.1298751","article-title":"A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas","volume":"58","author":"Sborov","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2025101505574819800_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/bjc.2011.527","article-title":"Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours","volume":"106","author":"Pili","year":"2012","journal-title":"Br J Cancer"},{"key":"2025101505574819800_bib44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00280-017-3382-x","article-title":"A phase I\/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript","volume":"80","author":"Grohar","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025101505574819800_bib45","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2025101505574819800_bib46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/jamp.2009.0812","article-title":"Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas\/FasL pathway and rationale for the use of gemcitabine","volume":"23","author":"Gordon","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2025101505574819800_bib47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/jamp.2009.0773","article-title":"Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs","volume":"23","author":"Rodriguez","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2025101505574819800_bib48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nbt.1759","article-title":"Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes","volume":"29","author":"Bantscheff","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2025101505574819800_bib49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1517\/17425255.2013.754011","article-title":"Toxicological and metabolic considerations for histone deacetylase inhibitors","volume":"9","author":"Fraczek","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025101505574819800_bib50","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/1541-7786.MCR-20-0833","article-title":"R-Loop-Mediated ssDNA breaks accumulate following short-term exposure to the HDAC inhibitor romidepsin","volume":"19","author":"Safari","year":"2021","journal-title":"Mol Cancer Res"},{"key":"2025101505574819800_bib51","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1021\/acs.biochem.7b00725","article-title":"Chemical editing of macrocyclic natural products and kinetic profiling reveal slow, tight-binding histone deacetylase inhibitors with picomolar affinities","volume":"56","author":"Kitir","year":"2017","journal-title":"Biochemistry"},{"key":"2025101505574819800_bib52","doi-asserted-by":"crossref","first-page":"10091","DOI":"10.1038\/ncomms10091","article-title":"Target engagement and drug residence time can be observed in living cells with BRET","volume":"6","author":"Robers","year":"2015","journal-title":"Nat Commun"},{"key":"2025101505574819800_bib53","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41589-022-01015-5","article-title":"Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target","volume":"18","author":"Lechner","year":"2022","journal-title":"Nat Chem Biol"},{"key":"2025101505574819800_bib54","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.molonc.2014.05.001","article-title":"Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin","volume":"8","author":"Luchenko","year":"2014","journal-title":"Mol Oncol"},{"key":"2025101505574819800_bib55","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025101505574819800_bib56","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Cancer Res"},{"key":"2025101505574819800_bib57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12967-016-0855-3","article-title":"Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids","volume":"14","author":"Halfter","year":"2016","journal-title":"J Transl Med"},{"key":"2025101505574819800_bib58","doi-asserted-by":"crossref","first-page":"11153","DOI":"10.1038\/s41598-019-47578-7","article-title":"Prospective validation of an ex vivo, patient-derived 3D spheroid model for response predictions in newly diagnosed ovarian cancer","volume":"9","author":"Shuford","year":"2019","journal-title":"Sci Rep"},{"key":"2025101505574819800_bib59","first-page":"vdab065","article-title":"Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay","volume":"3","author":"Shuford","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2025101505574819800_bib60","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41698-023-00463-z","article-title":"The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients","volume":"7","author":"\u00c5kerlund","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2025101505574819800_bib61","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.canlet.2018.10.033","article-title":"Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations","volume":"442","author":"Loh","year":"2019","journal-title":"Cancer Lett"},{"key":"2025101505574819800_bib62","doi-asserted-by":"crossref","first-page":"16991","DOI":"10.1038\/srep16991","article-title":"Identification of synergistic, clinically achievable, combination therapies for osteosarcoma","volume":"5","author":"Yu","year":"2015","journal-title":"Sci Rep"},{"key":"2025101505574819800_bib63","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1002\/mco2.317","article-title":"Integrated multiomic analysis and high-throughput screening reveal potential gene targets and synergetic drug combinations for osteosarcoma therapy","volume":"4","author":"Zhang","year":"2023","journal-title":"MedComm"},{"key":"2025101505574819800_bib64","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ijc.34027","article-title":"A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis","volume":"151","author":"Khalid","year":"2022","journal-title":"Int J Cancer"},{"key":"2025101505574819800_bib65","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.stem.2024.08.010","article-title":"The landscape of drug sensitivity and resistance in sarcoma","volume":"31","author":"Al Shihabi","year":"2024","journal-title":"Cell Stem Cell"},{"key":"2025101505574819800_bib66","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/cpt.3002","article-title":"Key pharmacokinetic parameters of 74 pediatric anticancer drugs providing assistance in preclinical studies","volume":"114","author":"Jamaladdin","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2025101505574819800_bib67","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41698-022-00335-y","article-title":"Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM","volume":"6","author":"Peterziel","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2025101505574819800_bib68","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1078-0432.CCR-23-0873","article-title":"Osteosarcoma PDX-derived cell line models for preclinical drug evaluation demonstrate metastasis inhibition by dinaciclib through a genome-targeted approach","volume":"30","author":"Schott","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025101505574819800_bib69","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/cjp2.210","article-title":"Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas","volume":"7","author":"Castillo-Ecija","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"2025101505574819800_bib70","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/cancers15010259","article-title":"Integrative multi-OMICs identifies therapeutic response biomarkers and confirms fidelity of clinically annotated, serially passaged patient-derived xenografts established from primary and metastatic pediatric and AYA solid tumors","volume":"15","author":"Pandya","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025101505574819800_bib71","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nrc4015","article-title":"Precision medicine for cancer with next-generation functional diagnostics","volume":"15","author":"Friedman","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2025101505574819800_bib72","doi-asserted-by":"crossref","first-page":"1600295","DOI":"10.1002\/biot.201600295","article-title":"Bringing 3D tumor models to the clinic - predictive value for personalized medicine","volume":"12","author":"Halfter","year":"2017","journal-title":"Biotechnol J"},{"key":"2025101505574819800_bib73","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cancergen.2016.03.004","article-title":"Current state of pediatric sarcoma biology and opportunities for future discovery: a report from the sarcoma translational research workshop","volume":"209","author":"Hingorani","year":"2016","journal-title":"Cancer Genet"},{"key":"2025101505574819800_bib74","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","article-title":"Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors","volume":"28","author":"Izumchenko","year":"2017","journal-title":"Ann Oncol"},{"key":"2025101505574819800_bib75","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/cncr.28696","article-title":"Patient-derived xenografts for individualized care in advanced sarcoma","volume":"120","author":"Stebbing","year":"2014","journal-title":"Cancer"},{"key":"2025101505574819800_bib76","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/cells8080889","article-title":"Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models","volume":"8","author":"Okada","year":"2019","journal-title":"Cells"},{"key":"2025101505574819800_bib77","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature23647","article-title":"Orthotopic patient-derived xenografts of paediatric solid tumours","volume":"549","author":"Stewart","year":"2017","journal-title":"Nature"},{"key":"2025101505574819800_bib78","doi-asserted-by":"crossref","first-page":"12174","DOI":"10.1038\/s41598-019-48634-y","article-title":"Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations","volume":"9","author":"Nanni","year":"2019","journal-title":"Sci Rep"},{"key":"2025101505574819800_bib79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","article-title":"Applications of patient-derived tumor xenograft models and tumor organoids","volume":"13","author":"Yoshida","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025101505574819800_bib80","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov"},{"key":"2025101505574819800_bib81","doi-asserted-by":"crossref","first-page":"71696","DOI":"10.18632\/oncotarget.12322","article-title":"Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy","volume":"7","author":"Hiroshima","year":"2016","journal-title":"Oncotarget"},{"key":"2025101505574819800_bib82","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/ng.3967","article-title":"Patient-derived xenografts undergo mouse-specific tumor evolution","volume":"49","author":"Ben-David","year":"2017","journal-title":"Nat Genet"},{"key":"2025101505574819800_bib83","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3892\/ijo.2012.1507","article-title":"Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1\/cip1 on the SP-B resistance or susceptibility of human leukemia cells","volume":"41","author":"Kanno","year":"2012","journal-title":"Int J Oncol"},{"key":"2025101505574819800_bib84","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1158\/1535-7163.MCT-23-0144","article-title":"The methyltransferases METTL7A and METTL7B confer resistance to thiol-based histone deacetylase inhibitors","volume":"23","author":"Robey","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2025101505574819800_bib85","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1124\/jpet.105.083956","article-title":"Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines","volume":"314","author":"Xiao","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"2025101505574819800_bib86","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1124\/jpet.108.147462","article-title":"Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone]","volume":"328","author":"Matsubara","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2025101505574819800_bib87","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1021\/pr7008753","article-title":"Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells","volume":"7","author":"Chen","year":"2008","journal-title":"J Proteome Res"},{"key":"2025101505574819800_bib88","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ijc.21297","article-title":"Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing\u2019s sarcoma cells","volume":"118","author":"Okada","year":"2006","journal-title":"Int J Cancer"},{"key":"2025101505574819800_bib89","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.cdd.4401507","article-title":"Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP","volume":"12","author":"Watanabe","year":"2005","journal-title":"Cell Death Differ"},{"key":"2025101505574819800_bib90","first-page":"664","article-title":"Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro","volume":"6","author":"Lutz","year":"2016","journal-title":"Am J Cancer Res"},{"key":"2025101505574819800_bib91","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bjc.2011.532","article-title":"Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide","volume":"106","author":"Chang","year":"2012","journal-title":"Br J Cancer"},{"key":"2025101505574819800_bib92","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1073\/pnas.0408732102","article-title":"Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors","volume":"102","author":"Ungerstedt","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025101505574819800_bib93","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.01.015","article-title":"The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitizer in bladder tumors in vivo","volume":"107","author":"Paillas","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025101505574819800_bib94","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/ijc.33046","article-title":"Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma","volume":"147","author":"McGuire","year":"2020","journal-title":"Int J Cancer"},{"key":"2025101505574819800_bib95","doi-asserted-by":"crossref","first-page":"9231","DOI":"10.1038\/sj.onc.1207184","article-title":"FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells","volume":"22","author":"Imai","year":"2003","journal-title":"Oncogene"},{"key":"2025101505574819800_bib96","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1158\/1078-0432.CCR-05-1225","article-title":"Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo","volume":"12","author":"Graham","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2025101505574819800_bib97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-030-43085-6_4","article-title":"Targeting the cancer epigenome with histone deacetylase inhibitors in osteosarcoma","volume":"1258","author":"Collier","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"2025101505574819800_bib98","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00280-010-1287-z","article-title":"The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin","volume":"67","author":"Wittenburg","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025101505574819800_bib99","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00280-010-1344-7","article-title":"Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells","volume":"67","author":"Yang","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025101505574819800_bib100","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/CAD.0000000000000418","article-title":"Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines","volume":"27","author":"Pettke","year":"2016","journal-title":"Anticancer Drugs"},{"key":"2025101505574819800_bib101","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12885-017-3046-6","article-title":"Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis","volume":"17","author":"Murahari","year":"2017","journal-title":"BMC Cancer"},{"key":"2025101505574819800_bib102","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.4161\/cc.10.18.17190","article-title":"Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer","volume":"10","author":"Luchenko","year":"2011","journal-title":"Cell Cycle"},{"key":"2025101505574819800_bib103","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.2174\/092986712802884286","article-title":"The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment","volume":"19","author":"Stiborov\u00e1","year":"2012","journal-title":"Curr Med Chem"},{"key":"2025101505574819800_bib104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","article-title":"Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention","volume":"1257","author":"Bhagat","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"2025101505574819800_bib105","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S1470-2045(10)70062-0","article-title":"Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects","volume":"11","author":"Janeway","year":"2010","journal-title":"Lancet Oncol"},{"key":"2025101505574819800_bib106","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13400","article-title":"Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data","volume":"170","author":"Bates","year":"2015","journal-title":"Br J Haematol"},{"key":"2025101505574819800_bib107","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2025101505574819800_bib108","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1158\/1078-0432.CCR-13-0109","article-title":"Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel","volume":"19","author":"Noonan","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0121\/3651014\/crc-25-0121.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/10\/1821\/3660360\/crc-25-0121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/10\/1821\/3660360\/crc-25-0121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:58:19Z","timestamp":1760522299000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/10\/1821\/766651\/Screening-FDA-Approved-Oncology-Drugs-with-Three"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":108,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0121","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8090893","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30364219","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364207","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364228","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364249","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364216","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364204","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364237","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364225","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364246","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364213","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364201","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364234","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364222","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364255","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364210","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364243","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364198","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364231","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364252","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30364240","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}